From genomes to vaccines: Leishmania as a model
Open Access
- 29 January 2002
- journal article
- Published by The Royal Society in Philosophical Transactions of the Royal Society B: Biological Sciences
- Vol. 357 (1417) , 5-11
Abstract
The 35 Mb genome of Leishmania should be sequenced by late 2002. It contains approximately 8500 genes that will probably translate into more than 10 000 proteins. In the laboratory we have been piloting strategies to try to harness the power of the genome–proteome for rapid screening of new vaccine candidate. To this end, microarray analysis of 1094 unique genes identified using an EST analysis of 2091 cDNA clones from spliced leader libraries prepared from different developmental stages of Leishmania has been employed. The plan was to identify amastigote–expressed genes that could be used in high–throughput DNA–vaccine screens to identify potential new vaccine candidates. Despite the lack of transcriptional regulation that polycistronic transcription in Leishmania dictates, the data provide evidence for a high level of post–transcriptional regulation of RNA abundance during the developmental cycle of promastigotes in culture and in lesion–derived amastigotes of Leishmania major . This has provided 147 candidates from the 1094 unique genes that are specifically upregulated in amastigotes and are being used in vaccine studies. Using DNA vaccination, it was demonstrated that pooling strategies can work to identify protective vaccines, but it was found that some potentially protective antigens are masked by other disease–exacerbatory antigens in the pool. A total of 100 new vaccine candidates are currently being tested separately and in pools to extend this analysis, and to facilitate retrospective bioinformatic analysis to develop predictive algorithms for sequences that constitute potentially protective antigens. We are also working with other members of the Leishmania Genome Network to determine whether RNA expression determined by microarray analyses parallels expression at the protein level. We believe we are making good progress in developing strategies that will allow rapid translation of the sequence of Leishmania into potential interventions for disease control in humans.Keywords
This publication has 19 references indexed in Scilit:
- HIV andLeishmaniaCoinfection: A Review of 91 Cases with Focus on Atypical Locations ofLeishmaniaClinical Infectious Diseases, 2000
- Gene expression data analysisFEBS Letters, 2000
- The Structure of Reduced Tryparedoxin Peroxidase Reveals a Decamer and Insight into Reactivity of 2Cys-peroxiredoxinsJournal of Molecular Biology, 2000
- Identification and characterisation of a functional peroxidoxin from Leishmania major1Note: Nucleotide sequence data reported in this paper are available in the EMBL, GenBank™ and DDJB databases under the accession number AF069386.1Molecular and Biochemical Parasitology, 1998
- Cloning, expression and reconstitution of the trypanothione-dependent peroxidase system of Crithidia fasciculata1Note: Nucleotide sequence data reported in this paper are available in the EMBL, GenBank and DDJB databases under the GenBank accession numbers AF055913 (tryparedoxin) and AF055914 (tryparedoxin peroxidase).1Molecular and Biochemical Parasitology, 1998
- The DNA-dependent protein kinase, DNA-PK: 10 years and no ends in sightBiochemistry and Cell Biology, 1996
- An expressed sequence tag analysis of a full-length, spliced-leader cDNA library from Leishmania major promastigotesMolecular and Biochemical Parasitology, 1996
- Nm23/nucleoside diphosphate kinase: Toward a structural and biochemical understanding of its biological functionsBioEssays, 1995
- Human c- myc Transcription Factor PuF Identified as nm23-H2 Nucleoside Diphosphate Kinase, a Candidate Suppressor of Tumor MetastasisScience, 1993
- EPIDEMIC VISCERAL LEISHMANIASIS IN SOUTHERN SUDANThe Lancet, 1989